Journey Medical Corp (DERM)vsTeva Pharma Industries Ltd ADR (TEVA)

DERM

Journey Medical Corp

NASDAQ

$5.97

-4.02%

HEALTHCARE · Cap: $166.03M

TEVA

Teva Pharma Industries Ltd ADR

NYSE

$34.43

-2.76%

HEALTHCARE · Cap: $40.32B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 26723% more annual revenue ($17.35B vs $64.68M). TEVA leads profitability with a 9.0% profit margin vs -14.8%. TEVA earns a higher WallStSmart Score of 66/100 (B-).

DERM

Avoid

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 4.5

Piotroski: 3/9Altman Z: -0.41

TEVA

Strong Buy

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 6.3Quality: 4.0

Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DERM1 strengths · Avg: 8.0/10

Revenue GrowthGrowth

21.5%8/10

Revenue surging 21.5% year-over-year

TEVA2 strengths · Avg: 9.0/10

EPS GrowthGrowth

72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation

0.858/10

Growing faster than its price suggests

Areas to Watch

DERM4 concerns · Avg: 3.0/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$166.03M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality

3/93/10

Weak financial health signals

Return on EquityProfitability

-31.1%2/10

ROE of -31.1% — below average capital efficiency

TEVA4 concerns · Avg: 3.0/10

P/E RatioValuation

25.8x4/10

Moderate valuation

Revenue GrowthGrowth

2.3%4/10

2.3% revenue growth

Free Cash FlowQuality

$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth

0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DERM

The strongest argument for DERM centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bear Case : DERM

The primary concerns for DERM are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

DERM profiles as a growth stock while TEVA is a value play — different risk/reward profiles.

DERM carries more volatility with a beta of 1.10 — expect wider price swings.

DERM is growing revenue faster at 21.5% — sustainability is the question.

DERM generates stronger free cash flow (3M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (66/100 vs 28/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Journey Medical Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks

DERM vs TAK DERM vs HLN DERM vs ZTS DERM vs UTHR DERM vs VTRS TEVA vs TAK TEVA vs HLN TEVA vs ZTS TEVA vs UTHR TEVA vs VTRS

Want to dig deeper into these stocks?

Full DERM Analysis →Full TEVA Analysis →